-+ 0.00%
-+ 0.00%
-+ 0.00%

Lineage Cell Therapeutics Expands Cell Transplant Pipeline With COR1

Benzinga·03/24/2026 12:07:08
Listen to the news
  • New Internally-Developed and Wholly-Owned Asset Benefits From Existing Ophthalmology and Manufacturing Expertise
    • Fuchs Endothelial Corneal Dystrophy (FECD) Afflicts More Than 7.3% of the Population with a Predicted 10-Year CAGR of 7.7%